Monitoring of Allergic and Asthmatic Symptoms in Patients Taking Dietary Supplements Joalis Bambi Bronchi and Joalis Bambi Analerg
Reduction of the total IgE antibody, improved vital capacity and lung volume measured by spirometry.
Improving quality of life observed in the visual analogue scale (VAS).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Karel Chroust, RNDr., Ing., PhD..
- Phone Number: +420 777 826 208
- Email: chroust@dscservices.cz
Study Locations
-
-
-
Zlín, Czech Republic, 760 01
- Recruiting
- Alergologicka ambulance
-
Contact:
- Albert Drštička, MUDr.
- Phone Number: +420 577 225 992
- Email: drstickalabert@seznam.cz
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- subjects with confirmed Asthma bronchiale I-III. degrees in possible combination with other allergic symptoms treating with classic pharmacological treatment
- 9-18 years
- signed Infromed Conset
Exclusion Criteria:
- subjects who have previously used a food suplemts Joalis
- subjects with known intolerance or hypersensitivity to the components of food supplements
- subjects with alcohol abuse or drugs at the time of recruitment into the study
- subjects enrolled in another clinical trial in the last 1 month before enrollment in this study
- subjects in a situation which in the opinion of a doctor may interfere with optimal participation in the study or can pose a risk to the subjects
- pregnant girls, lactating girls and girls of childbearing age without adequate contraception
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Joalis Bambi Bronchi & Joalis Bambi Analerg
10 days, 2 times per day 2,5/5 ml
|
|
|
Placebo Comparator: Placebo & Placebo
10 days, 2 times per day 2,5/5 ml
|
Sugar pill manufactured to mimic Joalis Bambi Analerg
Sugar pill manufactured to mimic Joalis Bambi Bronchi
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Reduction of the total IgE (IU/ml) antibody.
Time Frame: 1 year
|
1 year
|
|
Improving of vital capacity measured by spirometry (litre).
Time Frame: 1 year
|
1 year
|
|
Improving of lung volume measured by spirometry (litre).
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improving of quality of life observed in the visual analogue scale (VAS).
Time Frame: 1 year
|
1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Asthma bronchiale, age 9-18 year
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Karel Chroust, RNDr., Ing., PhD., DSC Services, s.r.o.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- KS-2011-05-JOALIS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.